Multiple choices for HIV therapy with integrase strand transfer inhibitors
1 University Hospital of Nantes, EA 4271, 1 Place Ricordeau, Nantes cedex 1 44093, France
2 McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, 3755 Côte-Sainte-Catherine Rd, Montreal, QC H3T 1E2, Canada
Retrovirology 2012, 9:110 doi:10.1186/1742-4690-9-110Published: 19 December 2012
Two integrases inhibitors, raltegravir and elvitegravir, have now been approved by regulatory agencies for use in the treatment of HIV-infected patients; and the approval of a third such drug, dolutegravir, is expected during 2013 on the basis of several phase 3 clinical trials. The advent of this new class of antiretroviral (ARV) medications represents a major advance in the management of HIV infection, and each of these three drugs can be expected to continue to be an important component of ARV combination regimens.